Activity Description
Ocular adverse events associated with antibody-drug conjugates are common, dose-limiting, and inadequately graded by current scales. This activity reviews corneal pseudomicrocyst pathophysiology, emerging consensus grading systems, and potential preventative strategies to improve oncology-ophthalmology coordination of care.
Sponsored by

![]()
Axiom Ophthalmic, LLC is a COPE-Approved Administrator.
This activity, COPE Activity Number 132954, is accredited by COPE for continuing education for optometrists. This course is approved for 0.25 hours of CE.
Course # 104546-PH
Activity #: 132954
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Release Date: 05-29-2026
Expiration Date: 05-28-2027
Target Audience
This accredited educational activity is designed for optometrists.
Grant Support Statement
This activity is supported by an unrestricted educational grant from AbbVie.
Faculty


Program Description
Ocular adverse events associated with antibody-drug conjugates are common, dose-limiting, and inadequately graded by current scales. This activity reviews corneal pseudomicrocyst pathophysiology, emerging consensus grading systems, and potential preventative strategies to improve oncology-ophthalmology coordination of care.
Expert Faculty
Learning Objectives
Credit Designation
Credit Hours: 0.25